Related Experiment Video
Updated: Jul 14, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Amiodarone therapy for atrial rhythm control: insights gained from a single center experience
Sheetal Chandhok1, David Schwartzman
1Cardiovascular Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Insights
Long-term amiodarone therapy for atrial fibrillation (AF) is not sustainable. After three years, only 45% of patients remained on amiodarone due to inefficacy, intolerance, or toxicity, including significant pulmonary issues.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Amiodarone is often recommended for long-term atrial fibrillation (AF) rhythm control.
- The long-term sustainability of this therapeutic strategy requires further investigation.
Purpose of the Study:
- To evaluate the long-term efficacy and tolerability of amiodarone for AF rhythm control.
- To assess the rate of amiodarone cessation and its causes over a 3-year period.
Main Methods:
- Retrospective analysis of 168 patients with symptomatic AF treated with amiodarone.
- Evaluation of amiodarone cessation rates at 1, 2, and 3 years.
- Categorization of cessation reasons: inefficacy, intolerance, or toxicity.
Main Results:
- Only 45% of patients continued amiodarone therapy at 3 years.
- Reasons for cessation included inefficacy (25%), intolerance (12%), and toxicity (18%).
- Pulmonary toxicity occurred in at least 7% of patients.
Conclusions:
- Amiodarone's long-term use for AF rhythm control is limited by cessation rates.
- The study challenges amiodarone's role as a definitive "destination" therapy for AF.
- Pulmonary toxicity is a significant concern with long-term amiodarone use.
Introduction:
Amiodarone has been advocated as an effective "long-term" therapy for atrial rhythm control in patients with atrial fibrillation (AF). We sought to assess the sustainability of this therapeutic strategy.
Methods And Results:
Retrospective analysis of a consecutive, single-center cohort (n = 168) with symptomatic AF who were treated with amiodarone and followed for 3 years. The incidence of amiodarone cessation was evaluated at 1, 2, and 3 years and attributed principally to drug inefficacy, intolerance, or toxicity. A gradual diminution in the number of patients on therapy was observed, such that by 3 years, only 45% remained. This was attributable to inefficacy (25%), intolerance (12%), or toxicity (18%). Pulmonary toxicity was surprisingly common, occurring in at least 7% of patients.
Conclusions:
These data challenge the notion of amiodarone as a reasonable "destination" therapy for AF.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias I: Introduction
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias IV: Characteristics of Bradyarrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

